HUMAW
Humacyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−78.05%Year over year
Reported trailing growth
- Revenue
- -73.6%
- EBITDA
- -95.0%
- EBIT
- +0.1%
- EPS
- -13.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +246.3%
- EBITDA
- +8.7%
- EPS
- +35.1%
Three-year CAGR
- Revenue
- +9.2%
- EBITDA
- +83.2%
- EBIT
- +6.1%
- Net income
- +72.5%
- EPS
- +79.4%
- Free cash flow
- -6.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026